Correlation Between Sika AG and Novozymes A/S

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sika AG and Novozymes A/S at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sika AG and Novozymes A/S into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sika AG and Novozymes AS B, you can compare the effects of market volatilities on Sika AG and Novozymes A/S and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sika AG with a short position of Novozymes A/S. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sika AG and Novozymes A/S.

Diversification Opportunities for Sika AG and Novozymes A/S

0.39
  Correlation Coefficient

Weak diversification

The 3 months correlation between Sika and Novozymes is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Sika AG and Novozymes AS B in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novozymes AS B and Sika AG is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sika AG are associated (or correlated) with Novozymes A/S. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novozymes AS B has no effect on the direction of Sika AG i.e., Sika AG and Novozymes A/S go up and down completely randomly.

Pair Corralation between Sika AG and Novozymes A/S

Assuming the 90 days horizon Sika AG is expected to generate 0.66 times more return on investment than Novozymes A/S. However, Sika AG is 1.52 times less risky than Novozymes A/S. It trades about 0.09 of its potential returns per unit of risk. Novozymes AS B is currently generating about 0.03 per unit of risk. If you would invest  23,558  in Sika AG on December 27, 2024 and sell it today you would earn a total of  2,212  from holding Sika AG or generate 9.39% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Sika AG  vs.  Novozymes AS B

 Performance 
       Timeline  
Sika AG 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Sika AG are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Sika AG may actually be approaching a critical reversion point that can send shares even higher in April 2025.
Novozymes AS B 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Novozymes AS B are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable primary indicators, Novozymes A/S is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders.

Sika AG and Novozymes A/S Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sika AG and Novozymes A/S

The main advantage of trading using opposite Sika AG and Novozymes A/S positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sika AG position performs unexpectedly, Novozymes A/S can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novozymes A/S will offset losses from the drop in Novozymes A/S's long position.
The idea behind Sika AG and Novozymes AS B pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Complementary Tools

Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Share Portfolio
Track or share privately all of your investments from the convenience of any device
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments